Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.0
(4.17%)
CNY 13.0
(4.17%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -507.5 Million CNY | -36.87% |
| 2022 | -370.8 Million CNY | -1048.33% |
| 2021 | 39.1 Million CNY | 106.81% |
| 2020 | -574.35 Million CNY | 36.56% |
| 2019 | -905.3 Million CNY | -182.62% |
| 2018 | -320.32 Million CNY | -190.38% |
| 2017 | 354.4 Million CNY | 27.55% |
| 2016 | 277.85 Million CNY | -15.53% |
| 2015 | 328.93 Million CNY | 79.44% |
| 2014 | 183.31 Million CNY | 28.9% |
| 2013 | 142.21 Million CNY | 36.29% |
| 2012 | 104.35 Million CNY | 28.96% |
| 2011 | 80.91 Million CNY | 55.38% |
| 2010 | 52.07 Million CNY | 30.74% |
| 2009 | 39.83 Million CNY | 59.29% |
| 2008 | 25 Million CNY | 44.55% |
| 2007 | 17.29 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 21.17 Million CNY | 106.15% |
| 2024 Q2 | -16.62 Million CNY | -178.51% |
| 2024 Q3 | -23.51 Million CNY | -41.43% |
| 2023 Q3 | -132.4 Million CNY | -160.3% |
| 2023 FY | -507.5 Million CNY | -36.87% |
| 2023 Q2 | -50.86 Million CNY | -351.94% |
| 2023 Q4 | -344.42 Million CNY | -160.13% |
| 2023 Q1 | 20.18 Million CNY | 109.09% |
| 2022 Q1 | -54.21 Million CNY | -136.23% |
| 2022 Q4 | -222.09 Million CNY | -370.03% |
| 2022 Q3 | -47.24 Million CNY | -0.0% |
| 2022 FY | -370.8 Million CNY | -1048.33% |
| 2022 Q2 | -47.24 Million CNY | 12.85% |
| 2021 Q3 | -86.03 Million CNY | -75.68% |
| 2021 Q1 | 24.44 Million CNY | 103.82% |
| 2021 Q2 | -48.97 Million CNY | -300.33% |
| 2021 Q4 | 149.65 Million CNY | 273.96% |
| 2021 FY | 39.1 Million CNY | 106.81% |
| 2020 FY | -574.35 Million CNY | 36.56% |
| 2020 Q4 | -640.09 Million CNY | -6493.65% |
| 2020 Q3 | 10.01 Million CNY | -64.09% |
| 2020 Q2 | 27.87 Million CNY | 0.09% |
| 2020 Q1 | 27.85 Million CNY | 103.44% |
| 2019 Q4 | -810.19 Million CNY | -358.3% |
| 2019 FY | -905.3 Million CNY | -182.62% |
| 2019 Q1 | 57.65 Million CNY | 109.06% |
| 2019 Q2 | 24.01 Million CNY | -58.35% |
| 2019 Q3 | -176.78 Million CNY | -836.15% |
| 2018 Q2 | 123.31 Million CNY | 17.4% |
| 2018 Q1 | 105.03 Million CNY | -1.16% |
| 2018 FY | -320.32 Million CNY | -190.38% |
| 2018 Q4 | -636.29 Million CNY | -826.18% |
| 2018 Q3 | 87.62 Million CNY | -28.94% |
| 2017 Q3 | 79.3 Million CNY | -5.59% |
| 2017 FY | 354.4 Million CNY | 27.55% |
| 2017 Q2 | 83.99 Million CNY | -0.98% |
| 2017 Q1 | 84.82 Million CNY | 103.58% |
| 2017 Q4 | 106.26 Million CNY | 34.0% |
| 2016 Q3 | 119.74 Million CNY | 118.39% |
| 2016 FY | 277.85 Million CNY | -15.53% |
| 2016 Q2 | 54.83 Million CNY | -10.99% |
| 2016 Q1 | 61.6 Million CNY | -58.27% |
| 2016 Q4 | 41.66 Million CNY | -65.2% |
| 2015 Q3 | 90.45 Million CNY | 75.78% |
| 2015 Q4 | 147.6 Million CNY | 63.19% |
| 2015 Q1 | 39.42 Million CNY | -43.92% |
| 2015 Q2 | 51.45 Million CNY | 30.54% |
| 2015 FY | 328.93 Million CNY | 79.44% |
| 2014 Q3 | 58.08 Million CNY | 89.67% |
| 2014 Q4 | 70.28 Million CNY | 21.02% |
| 2014 Q2 | 30.62 Million CNY | 25.9% |
| 2014 Q1 | 24.32 Million CNY | -63.68% |
| 2014 FY | 183.31 Million CNY | 28.9% |
| 2013 Q3 | 27.7 Million CNY | 2.88% |
| 2013 Q1 | 20.63 Million CNY | -36.34% |
| 2013 Q2 | 26.92 Million CNY | 30.51% |
| 2013 Q4 | 66.96 Million CNY | 141.75% |
| 2013 FY | 142.21 Million CNY | 36.29% |
| 2012 Q4 | 32.4 Million CNY | 16.83% |
| 2012 Q1 | 17.79 Million CNY | -43.94% |
| 2012 FY | 104.35 Million CNY | 28.96% |
| 2012 Q2 | 26.41 Million CNY | 48.41% |
| 2012 Q3 | 27.73 Million CNY | 5.03% |
| 2011 Q1 | 13.76 Million CNY | -34.52% |
| 2011 Q2 | 18.37 Million CNY | 33.47% |
| 2011 Q3 | 17.04 Million CNY | -7.24% |
| 2011 Q4 | 31.74 Million CNY | 86.29% |
| 2011 FY | 80.91 Million CNY | 55.38% |
| 2010 FY | 52.07 Million CNY | 30.74% |
| 2010 Q1 | 2.34 Million CNY | 0.0% |
| 2010 Q3 | 12.28 Million CNY | -25.28% |
| 2010 Q2 | 16.43 Million CNY | 601.92% |
| 2010 Q4 | 21.01 Million CNY | 71.16% |
| 2009 FY | 39.83 Million CNY | 59.29% |
| 2008 FY | 25 Million CNY | 44.55% |
| 2007 FY | 17.29 Million CNY | 0.0% |